Female Reproductive System Carcinosarcoma

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

10 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

8 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rucaparibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adavosertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afliberceptother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bendamustinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinib Mesylatesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Metforminsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mirvetuximab Soravtansineadc

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ruxolitinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Thalidomidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trabectedinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor

Female Reproductive System Carcinosarcoma studied in …STUDIED_INderived10 of 59show all (up to 200)
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 59 trials mapped (19 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03651206Phase 2/Phase 3 · recruiting Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07741968NA · recruiting A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 59 trials mapped (19 active)	—	—	Uterine Corpus Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03449108Phase 2 · active not recruiting LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05049538recruiting Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)	—	—	Uterine Corpus Carcinosarcoma	1	Observed	clinicaltrials	graph →

Female Reproductive System Carcinosarcoma studied in …STUDIED_INderived10 of 59show all (up to 200)

→ studied in

NCT05256225Phase 3 · recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT05920798Phase 1/Phase 2 · active not recruiting

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 59 trials mapped (19 active)

—

Observed

Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT02101775Phase 2 · active not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Observed

→ studied in

NCT03651206Phase 2/Phase 3 · recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Ovarian Carcinosarcoma

Observed

→ studied in

NCT07741968NA · recruiting

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Ovarian Carcinosarcoma

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT06580314Phase 3 · recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Observed

Uterine Corpus Carcinosarcoma

→ studied in

NCT03120624Phase 1 · active not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 59 trials mapped (19 active)

—

Observed

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

→ studied in

NCT04092270Phase 1 · active not recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Observed

→ studied in

NCT03449108Phase 2 · active not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Ovarian Carcinosarcoma

Observed

Uterine Corpus Carcinosarcoma

→ studied in

NCT05049538recruiting

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers · condition mapped ONTOLOGY_EXACT · 59 trials mapped (19 active)

—

Observed